Calcifilaxis no urémica mediada por acenocumarol

Francisco Ignacio Torres-Bondia; Federico Javier Parada-Saavedra; Josep Manel Fernández-Armenteros; Joan Antoni Schoenenberger-Arnaiz

doi:10.7399/fh.2017.41.4.10775

Calcifilaxis no urémica mediada por acenocumarol

Francisco Ignacio Torres-Bondia, Federico Javier Parada-Saavedra, Josep Manel Fernández-Armenteros, Joan Antoni Schoenenberger-Arnaiz

Resumen

Palabras clave

Texto completo:

PDF

Referencias

Nigwekar SU, Kroshinsky D, Nazarian RM, et al. Calciphylaxis: risk factors, diagnosis, and treatment. Am J Kidney Dis. 2015;66:133-46.

Aguirre C, García M. [Causality assessment in reports on adverse drug reactions. Algorithm of Spanish pharmacovigilance system]. Med Clin (Barc). 2016 Nov 18;147(10):461-64.

Yu WY, Bhutani T, Kornik R, Pincus LB, Mauro T, Rosenblum MD, Fox LP. Warfarin-Associated Nonuremic Calciphylaxis. JAMA Dermatol. 2017.

Huilaja L, Turpeinen M, Tokola H, Kauma H, Tasanen K, Ikäheimo R. Warfarininduced calciphylaxis in patients with normal renal function. J Clin Pharm Ther. 2016;41(4):449-52.

Schurgers LJ, Cranenburg EC, Vermeer C. Matrix Gla-protein: the calcification inhibitor in need of vitamin K. Thromb Haemost. 2008;100(4): 593-603.

DOI: http://dx.doi.org/10.7399%2Ffh.2017.41.4.10775